Consumers should not construe any information herein as medical advice or as a substitute for discussions with a prescribing practitioner or other qualified medical professional
Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026
Mousavinejad E, Ghaffari MA, Riahi F, Hajmohammadi M, Tiznobeyk Z, Mousavinejad M
Ansari SF, Khan A-u, Qazi NG, Shah FA, Naeem KJBRI
Effect of L-carnitine and raspberry ketones on metabolic parameters in Iraqi obese females, a comparative study
Omene plans to regularly measure blood samples and track changes in cancer markers, and biopsy participants' abdominal fat cells every six months, to see how those respond, in terms of hormones or inflammation